Disease-modifying Potential of TransdermalNICotine in Early Parkinson's Disease
A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of TransdermalNicotine in Early Parkinson's Disease in Germany and the USA A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying P ...
Parkinson's Disease
Drug: nicotinetransdermalpatch
James BOYD MD
Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkins ...
A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotinepatch. In this study the nicotinepatch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotinepatch but does not contain any active ingredients. A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be ...
A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermalnicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying p ...
Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levo ...
Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINETrade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NI ...
Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 Effet de la Nicotinetransdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une ...
Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 Effet de la Nicotinetransdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une ...
Trade Name: Nicorette 5 mg/ 16 h Product Name: Nicorette 5 mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 10mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 15 mg/ 16 h INN or Proposed INN: NicotineTrade Name: Nicorette 5 mg/ 16 h Product Name: Nicorette 5 mg/ 16 h INN or Proposed INN: Nicotine Produ ...